Departamento de Epidemiología, Unidad de Medicina Familiar No. 19, Instituto Mexicano del Seguro Social, Av. Javier Mina 301, Col. Centro, C.P. 28000, Colima, Colima, México; Facultad de Medicina, Universidad de Colima, Av. Universidad 333, Col. Las Víboras, C.P. 28040, Colima, Colima, México.
Centro Universitario de Investigaciones Biomédicas, Universidad de Colima, Av. 25 de julio 965, Col. Villas San Sebastián, C.P. 28045 Colima, México.
Int J Infect Dis. 2022 Jul;120:142-145. doi: 10.1016/j.ijid.2022.04.047. Epub 2022 Apr 25.
To compare, in a real-world scenario, the protective effect of vaccination and previous laboratory-confirmed symptomatic infection on the risk of COVID-19 pneumonia.
A retrospective study was conducted and 46,998 adults with laboratory-confirmed COVID-19 were enrolled. Risk ratios (RRs) and 95% confidence intervals (CIs) were used to evaluate the effect of the evaluated exposures on the risk of pneumonia.
In multiple analysis and after adjusting by reinfection status, vaccinated participants were at reduced risk of developing pneumonia (RR = 0.974, 95% CI 0.965-0.983). The association of having had a previous infection was not significant (RR = 1.001, 95% CI 0.969-1.034).
Our results suggest, and if later replicated, that COVID-19 vaccines provide better protection against pneumonia than previous symptomatic infections. Therefore, offering vaccination to all eligible subjects despite past COVID-19 infections might be relevant to reducing the pandemic-related burden.
在真实场景中比较疫苗接种和既往实验室确诊的有症状感染对 COVID-19 肺炎风险的保护作用。
进行了一项回顾性研究，共纳入 46998 例实验室确诊的 COVID-19 成年人。使用风险比（RR）和 95%置信区间（CI）评估评估暴露对肺炎风险的影响。
在多因素分析中，并调整再感染状态后，接种疫苗的参与者患肺炎的风险降低（RR=0.974，95%CI 0.965-0.983）。既往感染的相关性不显著（RR=1.001，95%CI 0.969-1.034）。
我们的结果表明，如果后续得到证实，那么 COVID-19 疫苗对肺炎的保护作用优于既往有症状感染。因此，对于所有符合条件的受试者，即使有既往 COVID-19 感染，提供疫苗接种可能有助于减轻大流行相关负担。
